China-based Shanxi Jinbo Bio-pharmaceutical Co., Ltd. (832982.BSE) is poised to raise RMB 36.75 million through a private placement on the Beijing Stock Exchange, supplementing the RMB 245 million initial public offering (IPO) proceeds the company recently acquired.
Jinbo Bio’s Industrialization of Recombinant Collagen Protein
Founded in 2008, Jinbo Bio has achieved industrialization in the production of recombinant collagen protein. The company has developed a 164.88 ° triple helix structure injection grade “A type humanized type III collagen new material” through synthetic biotechnology, marking a significant advancement in the field.
Growing Market for Recombinant Collagen
The market size for recombinant collagen is projected to reach RMB 108.3 billion by 2027, with an anticipated annual compound growth rate of 42.4% from 2022 to 2027. This growth potential underscores the importance of Jinbo Bio’s role in the industry and the significant opportunities available for the company as demand for recombinant collagen products increases.-Fineline Info & Tech
